regulatory
confidence high
sentiment positive
materiality 0.80
Arcutis submits NDA to FDA for roflumilast cream in plaque psoriasis
Arcutis Biotherapeutics, Inc.
- Submitted NDA for roflumilast cream (ARQ-151) to FDA for mild-to-severe plaque psoriasis.
- Indication covers adults and adolescents; submission date October 4, 2021.
- Roflumilast cream is a topical PDE4 inhibitor, a novel mechanism for psoriasis.